

Mark Kris

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5897505/mark-kris-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10 papers	5,314 citations	7 h-index	10 g-index
10 ext. papers	5,809 ext. citations	8.8 avg, IF	3.97 L-index

#	Paper	IF	Citations
10	Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis.. <i>Neuro-Oncology Advances</i> , 2021 , 3, vda187	8.9	0
9	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 709-740	8.9	77
8	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015 , 6, 22348-60	3.3	8
7	Acupuncture for the treatment of post-chemotherapy chronic fatigue: a randomized, blinded, sham-controlled trial. <i>Supportive Care in Cancer</i> , 2013 , 21, 1735-41	3.9	40
6	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <i>Nature Medicine</i> , 2008 , 14, 822-7	50.5	835
5	New approaches in the management of lung cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2005 , 3 Suppl 1, S22-4	7.3	
4	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 13306-11	11.5	3659
3	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 247-251	2.7	1
2	ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2240-50	2.2	666
1	The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 1999 , 86, 1720-1723	6.4	28